H.C. Wainwright raised the firm’s price target on Candel Therapeutics (CADL) to $19 from $11 and keeps a Buy rating on the shares. The company announced positive top-line data from its Phase 3 clinical trial with CAN-2409 in patients with intermediate-to-high risk localized prostate cancer, the analyst tells investors in a research note. The firm believes the probability of CAN-2409 as an off-the-shelf immunotherapy gaining regulatory approval has increased to 85% from a 35% probability of success.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CADL:
- Candel Therapeutics Inc call volume above normal and directionally bullish
- Broadcom tops $1T market cap on AI enthusiasm: Morning Buzz
- Morning Movers: Penn Entertainment rises following upgrade
- Candel Therapeutics 10M share Spot Secondary priced at $6.00
- Candel Therapeutics announces $80M common stock offering